Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)
Innovent Biologics, a leading biologics company in China, is raising up to USD 500 million to list in Hong Kong. In our previous insight (link...
576 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
687 Views
ECM Weekly (29 September 2018) - China Renaissance's First-Day Return Is the Worst in 2018
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
485 Views
Innovent Biologics (信达生物) IPO: A Major PD-1 MAb Competitor Might Have Just Emerged (Part 1)
Innovent Biologics is raising up to USD 500 million via a listing on the Hong Kong Stock Exchange. In this insight, we will discuss the following...
651 Views